Related Experiment Video
Updated: Jun 3, 2026
15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Castleman's disease: from basic mechanisms to molecular therapeutics
Hazem E El-Osta1, Razelle Kurzrock
1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), MD Anderson Cancer Center, Unit 455, P.O. Box 301402, Houston, Texas 77030, USA.
The Oncologist
|March 29, 2011
Summary
Castleman disease, a rare lymphoproliferative disorder, shows progress in understanding its mechanisms. New therapies targeting human herpes virus 8, CD20, and IL-6 offer hope for multicentric Castleman disease (MCD) treatment.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Castleman disease is a rare lymphoproliferative disorder with distinct clinical subtypes.
- Unicentric Castleman disease is typically indolent and managed with local therapies.
- Multicentric Castleman disease (MCD) presents a less favorable prognosis, necessitating systemic treatment.
Purpose of the Study:
- To review the current understanding of Castleman disease pathogenesis.
- To summarize established and emerging therapeutic strategies for MCD.
- To provide insights into future treatment directions based on disease biology.
Main Methods:
- Review of current literature on Castleman disease.
- Analysis of recent discoveries in disease mechanisms and therapeutic targets.
- Synthesis of information on treatment efficacy and toxicity.
Main Results:
- Cytotoxic chemotherapy has been a mainstay for MCD but shows variable efficacy and toxicity.
- Identification of human herpes virus 8, CD20, and interleukin-6 (IL-6) as key factors in MCD.
- Emergence of targeted therapies including rituximab and anti-IL-6 agents.
Conclusions:
- Advances in understanding MCD pathogenesis have led to targeted therapeutic approaches.
- Rituximab and anti-IL-6 therapies represent significant progress over traditional chemotherapy.
- Future strategies will likely focus on personalized treatment based on specific molecular targets.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...